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$2205 for salmeterol, $1911 for montelukast) in year 2.
There were no signiﬁcant differences in the adjusted
asthma-related health care costs and utilization. Although
the montelukast group showed higher compliance in the
bivariate analysis, this was not signiﬁcant in the multi-
variate regression. Overall ICS use decreased by 16% in
year 2 (p < 0.01), but there were no differences between
the two groups with regard to relative reduction of ICS
reﬁlls.
CONCLUSIONS: Adding either montelukast or salme-
terol as additional controller to ICS therapy was not 
associated with changes in either health care service 
utilization or costs in Medicaid-enrolled asthmatic
patients. However, their addition was associated with a
decrease in inhaled corticosteroid use, suggesting
decreased compliance in patients on the 2-drug regimen.
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OBJECTIVES: To estimate differences in length of stay
(LOS), emergency room (ER) visits and charges for 
inpatient asthma care between children and adults based
on insurance coverage, patient and hospital-based 
characteristics.
METHODS: The 1997 Nationwide Inpatient Sample of
the Healthcare Cost and Utilization Project data were
used to extract 183,400 childhood (age <17 years) and
251,760 adult asthma cases (primary diagnosis using
ICD-9 codes 493.00–493.91). Two-way ANOVA was
conducted to determine differences in LOS and total
charges between adult and childhood asthma based on
type of insurance coverage (Medicaid, private insur-
ance/HMO and self-pay) while chi-square analysis was
conducted to detect differences based on number of ER
visits. Regression models were developed separately for
childhood and adult asthma to examine if LOS and total
charges (multiple regression) and ER visits (logistic
regression) are affected by patient-related (race, gender,
number of co-morbidities and insurance status) and 
hospital-related (bed-size, location, teaching and 
ownership status) factors.
RESULTS: Overall, average length of stay for childhood
and adult asthma was 2.43 days and 3.98 days, respec-
tively. Mean total charges for childhood asthma was
$4,532 as compared to $7,713 for adult asthma. Almost
70% of adult asthmatics had ER visits as compared to
62% of asthmatic children. Adults had signiﬁcantly
higher total charges, LOS and ER visits for all types of
payers as compared to children. Medicaid-eligible adults
and children showed highest hospitalization charges, LOS
and ER visits. Non-whites, patients with higher number
of co-morbidities, urban and teaching hospitals were
associated with higher charges, LOS and ER visits, for
both adult and childhood asthma.
CONCLUSIONS: Adult asthmatics, especially Medicaid
beneﬁciaries, have higher inpatient charges, LOS and ER
visits as compared to asthmatic children. Future studies
should be aimed at reducing asthma-related ER visits and
investigating variations in resource utilization based 
on insurance coverage and patient and hospital-related
characteristics.
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OBJECTIVES: Comparative estimation cost and 
inﬂuence on quality of life in children with middle severe
asthma sodium cromoglycate and sodium nedocromil.
METHODS: Cost-utility analysis was conducted in
Child’s Municipal Asthma-Centre during 1998–2000
years in 100 children with asthma. We determined one
year expenses for quality adjusted life years (QALY). For
estimation quality of life we used “Childhood question-
naire” by A. West, D. French adapted for Russian by 
V. Petrov and I. Smolenov and index Rosser-Kind. 
Estimation of expenditures included direct and indirect
expenses.
RESULTS: The investigation revealed the differences in
therapeutic effectiveness and quality of life depending on
treatment method. Using therapy by nedocromil sodium
during one year, the total sum of positive effect on quality
of children’s life was 149,8%; health index 0,985 and
expenses on drug—3672,3 ± 40,4 roubles. Using 
sodium cromoglycate these indices were 70,9%; 0,965
and 1862,4 ± 24,2 roubles accordingly. Annual cost of
middle severe asthma for one child was 5051,4 ± 68,6
roubles using sodium nedocromil (72,7% expenditures
formed expenses on the drug); using sodium cromogly-
cate—5044,7 ± 110,4 roubles (36,92%) accordingly. In
the second case expenses on QALY were much more—
5207,65 in consequence of expenses on hospital care and
additional therapy.
CONCLUSIONS: Therapy by sodium cromoglycate of
middle severe asthma didn’t provide complete disease
control. In this case necessity in additional therapy for
improvement quality of life is increased.
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